9/29/2010:
Nuon Therapeutics Announces Gout Program Study Results to be Presented at the American College of Rheumatology
06/22/2010:
Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid Lowering Activity of Tranilast
06/16/2010:
Nuon Therapeutics Announces Positive Topline Results From a Phase 2a Study in Hyperuricemia
06/03/2010:
Nuon Therapeutics Announces Data Demonstrating Uric Acid Lowering Activity of Tranilast To Be Presented at EULAR 2010
05/13/2010:
Nuon Therapeutics Names Lee Rauch Chief Executive Officer
04/29/2010:
Nuon Therapeutics To Present Update On Programs In Rheumatoid Arthritis and Gout at 2010 BIO International Convention
04/21/2010:
Nuon Therapeutics Identifies Novel Use and Advances NU1618 into Development for Chronic Hyperuricemia in Patients with Gout
10/12/2009:
Nuon Therapeutics To Present At Biopartnering Europe
07/16/2009:
Affymax CEO Arlene Morris Joins Nuon Therapeutics’ Board of Directors as Chair
07/16/2009:
Nuon Therapeutics Appoints Paulette Dillon, Chief Business Officer, and Tito Serafini, Chief Scientific Officer
January 5, 2009
Nuon Therapeutics, Inc. Names Michael M. Kitt, M.D., Chief Medical Officer
April 28, 2008
Nuon Therapeutics, Inc. Completes $27 Million Series B Financing
July 23, 2007
Nuon Therapeutics, Inc. Completes Licensing, Supply And Collaboration Agreement On Tranilast With Kissei Pharmaceutical Co., Ltd.
July 20, 2007
Biotechnology Start-Up Nuon Therapeutics, Inc. Completes $5 Million Series A Financing And Names Management Team